182 related articles for article (PubMed ID: 37077705)
1. Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study.
Giron-Hernandez C; Han JH; Alberio R; Singh A; García-Portilla MP; Pompili M; Knight RK; Richarz U; Gopal S; Antunes J
Neuropsychiatr Dis Treat; 2023; 19():895-906. PubMed ID: 37077705
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.
Najarian D; Sanga P; Wang S; Lim P; Singh A; Robertson MJ; Cohen K; Schotte A; Milz R; Venkatasubramanian R; T'Jollyn H; Walling DP; Galderisi S; Gopal S
Int J Neuropsychopharmacol; 2022 Mar; 25(3):238-251. PubMed ID: 34791283
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study.
Richarz U; Han J; Bai YM; Yu-Hai Chen E; Chung YC; Jhanwar VG; Kim SW; Sulaiman AH; Knight K; Gopal S
Medicine (Baltimore); 2023 Aug; 102(34):e34623. PubMed ID: 37653768
[TBL] [Abstract][Full Text] [Related]
4. Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations.
Turkoz I; Daskiran M; Siddiqui U; Knight RK; Johnston KL; Correll CU
Int J Neuropsychopharmacol; 2024 Feb; 27(2):. PubMed ID: 38300235
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population.
Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Hough D; Hargarter L
Neuropsychiatr Dis Treat; 2019; 15():587-602. PubMed ID: 30863080
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.
Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Hough D; Mathews M; Feng Y; Yu L; Takahashi M; Liu D; Wang G; Yoon JS; Chen JJ
Neuropsychiatr Dis Treat; 2017; 13():2193-2207. PubMed ID: 28860777
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW
Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia.
Wang GH; Svensson M; Shao H; Vouri SM; Park H
J Manag Care Spec Pharm; 2023 Aug; 29(8):884-895. PubMed ID: 37523313
[No Abstract] [Full Text] [Related]
9. Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia.
Turkoz I; Wong J; Chee B; Siddiqui U; Knight RK; Richarz U; Correll CU
Ther Adv Psychopharmacol; 2023; 13():20451253231200258. PubMed ID: 37786804
[TBL] [Abstract][Full Text] [Related]
10. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
Mathews M; Pei H; Savitz A; Nuamah I; Hough D; Alphs L; Gopal S
Clin Drug Investig; 2018 Aug; 38(8):695-702. PubMed ID: 29882073
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia.
Najarian D; Turkoz I; Knight RK; Galderisi S; Lamaison HF; Zalitacz P; Aravind S; Richarz U
Int J Neuropsychopharmacol; 2023 Aug; 26(8):537-544. PubMed ID: 37480362
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies.
Savitz AJ; Xu H; Gopal S; Nuamah I; Mathews M; Soares B
Braz J Psychiatry; 2019; 41(6):499-510. PubMed ID: 30994855
[TBL] [Abstract][Full Text] [Related]
13. Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study.
Gopal S; Gogate J; Pungor K; Kim E; Singh A; Mathews M
Neuropsychiatr Dis Treat; 2020; 16():681-690. PubMed ID: 32184607
[TBL] [Abstract][Full Text] [Related]
14. Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I).
T'jollyn H; Russu A; Venkatasubramanian R; Gopal S; Nandy P; Neyens M; Faelens R; Samtani MN; Ackaert O; Perez-Ruixo JJ
Eur J Drug Metab Pharmacokinet; 2024 Jul; 49(4):477-489. PubMed ID: 38750386
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults.
Cirnigliaro G; Battini V; Castiglioni M; Renne M; Mosini G; Cheli S; Carnovale C; Dell'Osso B
Expert Rev Neurother; 2024 Apr; 24(4):325-332. PubMed ID: 38445396
[TBL] [Abstract][Full Text] [Related]
16. Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate.
Mathews M; Nuamah I; Savitz AJ; Hough DW; Najarian D; Kim E; Gopal S
Neuropsychiatr Dis Treat; 2018; 14():2807-2816. PubMed ID: 30498351
[TBL] [Abstract][Full Text] [Related]
17. Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II).
T'jollyn H; Venkatasubramanian R; Neyens M; Gopal S; Russu A; Nandy P; Perez-Ruixo JJ; Ackaert O
Eur J Drug Metab Pharmacokinet; 2024 Jul; 49(4):491-506. PubMed ID: 38769284
[TBL] [Abstract][Full Text] [Related]
18. Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia.
Li X; Ye C; Zhang W; Jia M; Wang G
CNS Drugs; 2024 Jan; 38(1):55-65. PubMed ID: 38190077
[TBL] [Abstract][Full Text] [Related]
19. Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate.
Morrison L; Lin D; Benson C; Ghelerter I; Vermette-Laforme M; Lefebvre P; Pilon D
J Manag Care Spec Pharm; 2023 Feb; 29(2):161-171. PubMed ID: 36354209
[No Abstract] [Full Text] [Related]
20. Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations.
Russu A; Savitz A; Mathews M; Gopal S; Feng Y; Samtani MN
J Clin Psychopharmacol; 2019; 39(6):567-574. PubMed ID: 31688450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]